PYC THERAPEUTICS LIMITED — Director's Dealing 2021

Feb 18, 2021

==> picture [595 x 179] intentionally omitted <==

----- Start of picture text ----- 19 February 2021CHANGE OF DIRECTOR’S INTEREST NOTICE----- End of picture text -----

Announcement

PYC Therapeutics, (ASX:PYC) (‘PYC’ or ‘the Company’), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, submits the following Appendix 3Y – Change of Director’s Interest Notice, in relation to Mr Alan Tribe.

This ASX announcement was approved and authorised for release by Sahm Nasseri US Chief Executive Officer.

ENDS For further information, please contact:

INVESTORS MEDIA Deborah Elson/Matthew DeYoung Leo Vartorella Argot Partners Argot Partners deborah@argotpartners.com leo@argotpartners.com matthew@argotpartners.com

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize Cell Penetrating Peptides (CPPs), a revolutionary delivery technology designed to overcome the major challenges of current gene-based therapies. PYC believes its CPP technology provides safer, more effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which it has unveiled three preclinical stage assets. PYC’s discovery and laboratory operations are located in Australia and the Company recently launched and expansion into the U.S. for its preclinical, clinical, regulatory and business development operations. For more information, visit pyctx.com, or follow us on LinkedIn and Twitter .

1

+61 8 6151 0994 | pyctx.com | ACN 098 391 961

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

2

+61 8 6151 0992 | pyctx.com | ACN 098 391 961

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PYC THERAPEUTICS LIMITED ABN 48 098 391 961

We, Phylogica Limited, give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

for the director for the purposes of section	205G of the Corporations Act.
Name of Director	Alan William Tribe
Date of last notice	28 October 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest	Mr Tribe is a Director of Australian Land Pty
(including registered holder)	Ltd, Delarge Investments Pty Ltd, Runcton Pty
Note: Provide details of the circumstances giving rise to the relevantinterest.	Ltd, Pagham Pty Ltd and Stockbridge
	Corporation Pty Ltd.
Date of change	17 February 2021
**No. of securities heldprior to change **	970,820,136 Ordinary Shares
Class	Ordinary Shares
Number acquired	600,000
Nature of change	On market purchase
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buy-
back
Number disposed	Nil
Value/Consideration	$0.135 per Ordinary Share
Note: If consideration is non-cash, provide details and estimated
valuation
**No. of securities held after change **	971,420,136 Ordinary Shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where priorwritten clearance was required?	No
If so, was prior written clearance provided to allow thetrade to proceed during this period?
If prior written clearance was provided, on what datewas this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011